Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | S100B | P04271 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27757603 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL274140 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL2249056 | 0.81 | ALDH1A1 (0.43) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL16526926 | 0.79 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL14036541 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL12345636 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL17298240 | 0.76 | CYP3A4 (0.55) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL273646 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL8732134 | 0.76 | ALDH1A1 (0.64) | ALDH1A1CYP1A2ALOX15CASP7HIF1A | |
| SCHEMBL6510330 | 0.75 | GRIN2D (0.36) | ALOX15NOS3NOS1NOS2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010489-B1 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687521-B2 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-7524965-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2010489-A2 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127196-A2 | DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | ALDH1A1 772/4885CYP1A2 221/4885ALOX15 2632/4885 |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | ALDH1A1 772/4885CYP1A2 221/4885ALOX15 2632/4885 |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRB1, ADRA2C | ALDH1A1 772/4885CYP1A2 221/4885ALOX15 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.